NEW YORK (GenomeWeb) – French diagnostic and theranostics firm Theradiag announced on Thursday that it has signed an agreement under which its Lisa Tracker monitoring kits will be referenced in supply contracts for Merck's immunosuppressant Remicade (infliximab) in France.
Remicade is a tumor necrosis factor-alpha (TNF-alpha) inhibitor used to treat a range of diseases including Crohn's disease, psoriasis, and rheumatoid arthritis. Lisa Tracker kits are designed to monitor serum levels of circulating TNF-alpha, prescribed TNA-alpha inhibitors, and drug neutralizing antibodies to help physicians manage treatment regimens.
Under the terms of their deal, Merck's French subsidiary, MSD France, will reference Lisa Tracker in contracts to supply Remicade. Theradiag will be responsible for supplying and implementing the kits, as well as training laboratory personnel in their use and following up with monitoring-related requests by clinicians.
Additional terms were not disclosed.